切换至 "中华医学电子期刊资源库"

中华普外科手术学杂志(电子版) ›› 2020, Vol. 14 ›› Issue (04) : 396 -398. doi: 10.3877/cma.j.issn.1674-3946.2020.04.022

所属专题: 文献

论著

经皮肝穿刺胆管引流术对肝门部胆管癌的临床疗效及预后分析
梁先春1, 王伟1,(), 林启超2   
  1. 1. 400016 陆军特色医学中心肝胆外科
    2. 610031 成都大学附属医院肝胆外科
  • 收稿日期:2019-12-09 出版日期:2020-08-26
  • 通信作者: 王伟

Clinical effect and prognosis of hilar cholangiocarcinoma treated by using percutaneous transhepatic biliary drainage

Xianchun Liang1, Wei Wang1,(), Qichao Lin2   

  1. 1. Department of Hepatobiliary Surgery, Army characteristic Medical Center, Chongqing 400016, China
    2. Department of Hepatobiliary Surgery, the affiliated Hospital of Chengdu University, Sichuan 610031, China
  • Received:2019-12-09 Published:2020-08-26
  • Corresponding author: Wei Wang
  • About author:
    Corresponding author: Wang Wei, Email:
  • Supported by:
    Scientific Research Project of Sichuan Health and Family Planning Commission(16PJ001)
引用本文:

梁先春, 王伟, 林启超. 经皮肝穿刺胆管引流术对肝门部胆管癌的临床疗效及预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2020, 14(04): 396-398.

Xianchun Liang, Wei Wang, Qichao Lin. Clinical effect and prognosis of hilar cholangiocarcinoma treated by using percutaneous transhepatic biliary drainage[J/OL]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2020, 14(04): 396-398.

目的

探究经皮肝穿刺胆管引流术(PTBD)对Bismuth-Corlette I/II型肝门部胆管癌(HCCA)临床治疗效果及预后的影响。

方法

回顾性分析2011年8月至2013年3月78例I/II型HCCA患者资料,其中42例患者采用PTBD治疗,设为PTBD组;36例患者采用经内镜鼻胆管引流术(ENBD)治疗,设为ENBD组。采用SPSS22.0软件进行分析,治疗前后肝功能指标等计量资料以(±s)描述,独立t检验;引流成功率和并发症发生率采用χ2检验分析;5年生存率采用KaplanMeier法进行生存分析,进行LogRank检验。P<0.05差异有统计学意义。

结果

PTBD组引流操作成功率85.7%(36/42)显著高于ENBD组63.9%(23/36), P<0.05;治疗后两组患者的TBA、TB、ALP和ALT水平均较治疗前有明显降低(P<0.05);PTBD组术后并发症率9.5%显著低于ENBD组27.8%(P=0.036);PTBD组5年生存率21.4%、平均生存时间(3.5±1.7)年;显著高于ENBD组5.6%(2.4±1.5)年,差异均有统计学意义(P<0.05)。

结论

采用PTBD治疗I/II期型肝门胆管癌的临床疗效良好,可改善患者的肝功能,降低并发症发生率,提高患者5年生存率,值得临床推广应用。

Objective

To investigate the clinical effect and to analyze the prognosis of Bismith corlette I/II hilar cholangiocarcinoma treated by using percutaneous transhepatic biliary drainage (PTBD).

Methods

From August 2011 to March 2013, 78 patients with Bismith corlette I/II hilar cholangiocarcinoma were enrolled into present study, among whom 42 patients received PTBD (PTBD group) and 36 patients received endoscopic nasobiliary drainage (ENBD group). Statistical analysis were performed by using SPSS22.0 software. Measurement data such as perioperative liver function index were described by (±s) and were analyzed by using independent t test. Counting data such as success rate of drainage, incidence of complications were analyzed by using χ2 test. 5-year-survival analysis was performed by using Kaplan-Meier method. A P value <0.05 was considered as statistically significant difference.

Results

Compared with patients in the ENBD group, the success rate of drainage in the PTBD group was significantly higher (85.7% vs. 63.9%, P<0.05); The levels of TBA, TB, ALP and ALT in both 2 groups were significantly decreased after drainage treatment(P<0.05). The incidence of complications of 9.5% in the PTBD group was significantly lower than 27.8% in the ENBD group (P=0.036). The 5-year survival of 21.4% in the PTBD group ( with average of 3.5±1.7 years) was significantly higher than 5.6% in the ENBD group (with average of 2.4±1.5 years) (P=0.004).

Conclusion

The clinical efficacy of PTBD in the treatment of Bismith corlette I/II hilar cholangiocarcinoma is satisfactory, which could improve the liver function, reduce the risk of complications, and improve the 5-year survival of patients. It is worthy of wider clinical application.

表1 78例HCCA患者不同疗法两组患者的基本临床资料比较[(±s),例]
表2 78例HCCA患者不同疗法两组患者的并发症情况比较[例(%)]
表3 78例HCCA患者不同疗法两组患者治疗前后肝功能指标比较(±s)
图1 78例HCCA患者不同疗法两组患者随访5年的生存曲线
[1]
何敏,王坚. 肝门部胆管癌术前可切除性评估的方法与意义[J]. 临床外科杂志,2017, 25(6): 419-422.
[2]
尹大龙,刘连新. 肝门部胆管癌根治性切除术前评估策略[J]. 肝胆外科杂志,2017, 25(2): 84-86.
[3]
殷晓煜. 肝门部胆管癌术前行胆道引流术减轻黄疸的争议与策略[J]. 中华消化外科杂志,2018, 17(3): 229-232.
[4]
唐明尧,陈勇. 肝门部胆管癌临床治疗的研究进展[J]. 中华肝胆外科杂志,2017, 23(12): 857-860.
[5]
丁天龙,马延龄,王丹,等. 肝门部胆管癌的围手术期处理[J]. 国际外科学杂志,2018, 45(6): 418-422,封4.
[6]
王鹏飞,朱自满,蔡守旺. 肝门部胆管癌的切除与重建[J]. 临床外科杂志,2017, 25(3): 177-178.
[7]
隋鑫磊,汤恢焕,肖广发,等. 肝门部胆管癌姑息治疗的效果及预后分析:附218例报告[J]. 中国普通外科杂志,2017, 26(8): 953-959.
[8]
刘中,鲁正. 不同术前胆道引流方式治疗肝门胆管癌疗效的Meta分析[J]. 中华肝胆外科杂志,2018, 24(10): 681-686.
[9]
张东,陶杰,耿智敏,等. 联合半肝切除肝门部胆管癌63例预后分析[J]. 西部医学,2017, 29(7): 927-930,934.
[10]
中华医学会外科学分会胆道外科学组,解放军全军肝胆外科专业委员会. 肝门部胆管癌诊断和治疗指南(2013版) [J]. 中华外科杂志,2013, 51(10): 865-871.
[11]
唐友银,陈哲宇.高胆红素下对Bismuth-Corlette Ⅳ型肝门胆管癌患者实施根治性切除术的报道[J]. 中国普外基础与临床杂志,2018, 25(5): 602-607.
[12]
董家鸿,叶晟. 不断提高肝门部胆管癌切除的精准化水平[J/CD]. 中华普外科手术学杂志:电子版,2015, 9(5): 1-4.
[13]
肖青川,胡红强,李佳俊,等. 肝门部胆管癌外科治疗的生存状况研究[J]. 中国现代普通外科进展,2017, 20(7): 543-545,548.
[14]
魏建,李洪璐,郭江,等. 复合胆道引流术治疗Bismuth Ⅳ型Klatskin肿瘤所致恶性梗阻性黄疸[J]. 中国介入影像与治疗学,2018, 15(6): 337-340.
[15]
张辉,张振,张海涛,等. 肝门部胆管癌根治术前经内镜鼻胆管引流和经皮经肝胆管造影引流术的临床效果观察[J]. 腹部外科,2017, 30(3): 197-201.
[16]
郑泰. 经皮经肝穿刺胆管引流术在肝门部胆管癌治疗中的近期效果分析[J]. 检验医学与临床,2018, 15(12): 1774-1776, 1779.
[17]
张隽,乔岐禄,吴问汉,等. 术前经皮经肝胆道穿刺引流及门静脉栓塞联合扩大肝切除术治疗局部进展期肝门部胆管癌[J]. 中华肝胆外科杂志,2017, 23(3): 173-175.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[3] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[4] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[5] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[6] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[7] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[8] 张润锦, 阳盼, 林燕斯, 刘尊龙, 刘建平, 金小岩. EB病毒相关胆管癌伴多发转移一例及国内文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 865-869.
[9] 陈晓鹏, 王佳妮, 练庆海, 杨九妹. 肝细胞癌VOPP1表达及其与预后的关系[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 876-882.
[10] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11] 陈倩倩, 袁晨, 刘基, 尹婷婷. 多层螺旋CT 参数、癌胚抗原、错配修复基因及病理指标对结直肠癌预后的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 507-511.
[12] 曾明芬, 王艳. 急性胰腺炎合并脂肪肝患者CT 与彩色多普勒超声诊断参数与其病情和预后的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 531-535.
[13] 沈炎, 张俊峰, 唐春芳. 预后营养指数结合血清降钙素原、胱抑素C及视黄醇结合蛋白对急性胰腺炎并发急性肾损伤的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 536-540.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要